Abstract
The endogenous cannabinoid system regulates diverse aspects of physiological functions via specific cannabinoid receptors (CB) expressed in the brain and periphery. CB1 receptors mediate various neurological processes, whereas CB2 receptors mainly regulate immune responses and are involved in development of drug addiction and neuroinflammation. The cannabinoids are a heterogeneous group of endo-, phyto-, and synthetic cannabinoids. Cannabis and its products have been used for millennia, and these remain the most frequently used substances around the world. Δ9-Tetrahydrocannabinol (Δ9-THC), the main psychoactive constituent of cannabis, produces psychotic-like symptoms. Acute and chronic cannabis use may impair learning and memory, attention, and psychomotor functions; however, studies on the life-lasting effects of cannabis on brain structure are ambiguous. During the last decade, a worrying trend has been observed regarding the increasing popularity of more potent, addictive, and harmful synthetic cannabinoids (SCs). Unlike Δ9-THC, SCs use may lead to severe adverse effects including seizures, agitation, aggression, violence, anxiety, and panic attacks. Acute intoxication may be life-threatening or lead to persistent impairments in emotional and cognitive processing as a result of irreversible brain damage. This chapter describes the current state of knowledge regarding various aspects of the neurotoxicity of exogenous cannabinoids, including the harmful effects of their use during pregnancy.
Similar content being viewed by others
Abbreviations
- 2-AG:
-
2-Arachidonoylglycerol
- AEA:
-
N-arachidonoylethanolamine
- CB1:
-
Type 1 cannabinoid receptor
- CB2:
-
Type 2 cannabinoid receptor
- CBC:
-
Cannabichromene
- CBD:
-
Cannabidiol
- CBG:
-
Cannabigerol
- CBN:
-
Cannabinol
- CPP:
-
Conditioned place preference
- CUD:
-
Cannabis use disorder
- DAG:
-
Diacylglycerol
- DAGLα:
-
Diacylglycerol lipase-α
- EMCDDA:
-
European Monitoring Centre for Drugs and Drug Addiction
- FAAH:
-
Fatty acid amide hydrolase
- IVSA:
-
Intravenous self-administration
- ICSS:
-
Intracranial self-stimulation
- MAGL:
-
Monoacylglycerol lipase
- NPS:
-
New psychoactive substances
- SCs:
-
Synthetic cannabinoids
- UNODC:
-
United Nations Office on Drugs and Crime
- Δ9-THC:
-
Δ9-Tetrahydrocannabinol
References
Alipour, A., Patel, P. B., Shabbir, Z., & Gabrielson, S. (2019). Review of the many faces of synthetic cannabinoid toxicities. The Mental Health Clinician, 9(2), 93–99.
Alpar, A., Di Marzo, V., & Harkany, T. (2016). At the tip of an iceberg: Prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry, 79(7), e33–e45.
Alves, V. L., Gonçcalves, J. L., Agular, J., Teixeira, H. M., & Câmara, J. S. (2020). The synthetic cannabinoids phenomenon: From structure to toxicological properties. A review. Critical Reviews in Toxicology, 50(5), 359–382.
Antinori, S., & Fattore, L. (2017). How CB1 receptor activity and distribution contribute to make the male and female brain different toward cannabinoid-induced effects. In M. Melis (Ed.), Endocannabinoids and Lipid Mediators in Brain Functions (pp. 27–51). Springer.
Antonelli, T., Tomasini, M. C., Tattoli, M., Cassano, T., Finetti, S., Mazzoni, E., Trabace, L., Carratù, M. R., Cuomo, V., Tanganelli, S., & Ferraro, L. (2006). Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures. Neurochemistry International, 49(6), 568–576.
Bahji, A., Stephenson, C., Tyo, R., Hawken, E. R., & Seitz, D. P. (2020). Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: A systematic review and meta-analysis. JAMA Network Open, 3, e202370.
Banister, S. D., & Connor, M. (2018). The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. Handbook of Experimental Pharmacology, 252, 165–190.
Barratt, M. J., Cakic, V., & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32(2), 141–146.
Bertrand, K. A., Hanan, N. J., Honerkamp-Smith, G., Best, B. M., & Chambers, C. D. (2018). Marijuana use by breastfeeding mothers and cannabinoid concentrations in breast milk. Pediatrics, 142(3), e20181076.
Bilel, S., Tirri, M., Arfè, R., Stopponi, S., Soverchia, L., Ciccocioppo, R., Frisoni, P., Strano-Rossi, S., Miliano, C., De-Giorgio, F., Serpelloni, G., Fantinati, A., De Luca, M. A., Neri, M., & Marti, M. (2019). Pharmacological and behavioral effects of the synthetic cannabinoid AKB48 in rats. Frontiers in Neuroscience, 13, 1163.
Blest-Hopley, G., Giampietro, V., & Bhattacharyya, S. (2020). A systematic review of human neuroimaging evidence of memory-related functional alterations associated with cannabis use complemented with preclinical and human evidence of memory performance alterations. Brain Sciences, 10, 102.
Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrome: Current insights. Substance Abuse and Rehabilitation, 8, 9–37.
Breivogel, C. S., Wells, J. R., Jonas, A., Mistry, A. H., Gravley, M. L., Patel, R. M., Whithorn, B. E., & Brenseke, B. M. (2020). Comparison of the neurotoxic and seizure-inducing effects of synthetic and endogenous cannabinoids with Δ9-tetrahydrocannabinol. Cannabis and Cannabinoid Research, 5(1), 32–34.
Campolongo, P., Trezza, V., Palmery, M., Trabace, L., & Cuomo, V. (2009). Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. International Reviews of Neurobiology, 85, 117–133.
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016). Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research, 112, 119–127.
Canazza, I., Ossato, A., Vincenzi, F., Gregori, A., Di Rosa, F., Nigro, F., Rimessi, A., Pinton, P., Varani, K., Borea, P. A., & Marti, M. (2017). Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Human Psychopharmacology: Clinical and Experimental, 32(3), e:2601.
Castelli, M. P., Fadda, P., Casu, A., Spano, M. S., Casti, A., Fratta, W., & Fattore, L. (2014). Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: Effect of ovarian hormones. Current Pharmaceutical Design, 20(13), 2100–2113.
Cengel, H. Y., Bozkurt, M., Evren, C., Umut, G., Keskinkilic, C., & Agachanli, R. (2018). Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Research, 262, 46–54.
Chan, G. C., Hinds, T. R., Impey, S., & Storm, D. R. (1998). Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. The Journal of Neuroscience, 18(14), 5322–5332.
Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). European Archives of Psychiatry and Clinical Neuroscience, 269, 5–15.
Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.
Chye, Y., Kirkham, R., Lorenzetti, V., McTavish, E., Solowij, N., & Yücel, M. (2021). Cannabis, cannabinoids, and brain morphology: A review of the evidence. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 6(6), 627-635.
Cohen, K., Mama, Y., Rosca, P., Pinhasov, A., & Weinstein, A. (2020). Chronic use of synthetic cannabinoids is associated with impairment in working memory and mental flexibility. Frontiers in Psychiatry, 11, 602.
Colizzi, M., & Bhattacharyya, S. (2017). Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports, 4, 62–74.
Cooper, Z. D., & Craft, R. M. (2018). Sex-dependent effects of cannabis and cannabinoids: A translational perspective. Neuropsychopharmacology, 43(1), 34–51.
Cooper, Z. D., & Haney, M. (2009). Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. International Review of Psychiatry, 21(2), 104–112.
Davis, J. P., Smith, D. C., Morphew, J. W., Lei, X., & Zhang, S. (2016). Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: A prospective study. Journal of Drug Issues, 46(1), 64–83.
De Luca, M. A., & Fattore, L. (2018). Therapeutic use of synthetic cannabinoids: Still an open Issue? Clinical Therapeutics, 40(9), 1457–1466.
De Luca, M. A., Castelli, M. P., Loi, B., Porcu, A., Martorelli, M., Miliano, C., Kellett, K., Davidson, C., Stair, L. J., Schifano, F., & Di Chiara, G. (2016). Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology, 105, 630–638.
del Arco, I., Muñoz, R., Rodríguez De Fonseca, F., Escudero, L., Martín-Calderón, J. L., Navarro, M., & Villanúa, M. A. (2000). Maternal exposure to the synthetic cannabinoid HU-210: Effects on the endocrine and immune systems of the adult male offspring. Neuroimmunomodulation, 7(1), 16–26.
DiNieri, J. A., Wang, X., Szutorisz, H., Spano, S. M., Kaur, J., Casaccia, P., Dow-Edwards, D., & Hurd, Y. L. (2011). Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biological Psychiatry, 70(8), 763–769.
Downer, E., Boland, B., Fogarty, M., & Campbell, V. (2001). Δ9-Tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport, 12(18), 3973–3978.
El Marroun, H., Tiemeier, H., Franken, I. H., Jaddoe, V. W., van der Lugt, A., Verhulst, F. C., Lahey, B. B., & White, T. (2016). Prenatal cannabis and tobacco exposure in relation to brain morphology: A prospective neuroimaging study in young children. Biological Psychiatry, 79(12), 971–979.
ElSohly, M. A., Radwan, M. M., Gul, W., Chandra, S., & Galal, A. (2017). Phytochemistry of Cannabis sativa L. Progress in Chemistry of Organic Natural Products, 103, 1–36.
EMCDDA. (2019a). EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances. https://www.emcdda.europa.eu/system/files/publications/12213/EWS%20guidelines_final.pdf. Accessed 12 Nov 2020.
EMCDDA. (2019b). European drug report 2019: Trends and developments. https://www.emcdda.europa.eu/publications/edr/trends-developments/2019. Accessed 29 Oct 2020.
EMCDDA. (2019c). Developments in the European cannabis market. https://www.emcdda.europa.eu/publications/emcdda-papers/developments-in-the-european-cannabis-market. Accessed 3 Feb 2021.
EMCDDA. (2020). European drug report 2020: Trends and developments. https://www.emcdda.europa.eu/system/files/publications/13236/TDAT20001ENN_web.pdf. Accessed 2 Nov 2020.
Fattore, L. (2016). Synthetic cannabinoids – Further evidence supporting the relationship between cannabinoids and psychosis. Biological Psychiatry, 79(7), 539–548.
Fattore, L., & Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 60.
Fattore, L., Cossu, G., Martellotta, C. M., & Fratta, W. (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl), 156(4), 410–416.
Fattore, L., Spano, M. S., Altea, S., Fadda, P., & Fratta, W. (2010). Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: Influence of ovarian hormones. British Journal of Pharmacology, 160(3), 724–735.
Fattore, L., Marti, M., Mostallino, R., & Castelli, M. P. (2020). Sex and gender differences in the effects of Novel Psychoactive Substances. Brain Sciences, 10(9), 606.
Ford, T. C., Hayley, A. C., Downey, L. A., & Parrott, A. C. (2017). Cannabis: An overview of its adverse acute and chronic effects and its implications. Current Drug Abuse Reviews, 10(1), 6–18.
Frau, R., Miczán, V., Traccis, F., Aroni, S., Pongor, C. I., Saba, P., Serra, V., Sagheddu, C., Fanni, S., Congiu, M., Devoto, P., Cheer, J. F., Katona, I., & Melis, M. (2019). Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nature Neuroscience, 22(12), 1975–1985.
Freels, T. G., Baxter-Potter, L. N., Lugo, J. M., Glodosky, N. C., Wright, H. R., Baglot, S. L., Petrie, G. N., Yu, Z., Clowers, B. H., Cuttler, C., Fuchs, R. A., Hill, M. N., & McLaughlin, R. J. (2020). Vaporized cannabis extracts have reinforcing properties and support conditioned drug-seeking behavior in rats. The Journal of Neuroscience, 40(9), 1897–1908.
Freeman, T. P., Groshkova, T., Cunningham, A., Sedefov, R., Griffiths, P., & Lynskey, M. T. (2019). Increasing potency and price of cannabis in Europe, 2006–2016. Addiction, 114(6), 1015–1023.
Funada, M., & Takebayashi-Ohsawa, M. (2018). Synthetic cannabinoid AM2201 induces seizures: Involvement of cannabinoid CB1 receptors and glutamatergic transmission. Toxicology and Applied Pharmacology, 338, 1–8.
Gamage, T. F., Farquhar, C. E., Lefever, T. W., Marusich, J. A., Kevin, R. C., McGregor, I. S., Wiley, J. L., & Thomas, B. F. (2018). Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. The Journal of Pharmacology and Experimental Therapeutics, 365(2), 437–446.
Gatch, M. B., & Forster, M. J. (2019). Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. Neurotoxicology, 70, 72–79.
Gilbert, G. L., Kim, H. J., Waataja, J. J., & Thayer, S. A. (2007). Δ9-Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Research, 1128, 61–69.
Gilbert, M. T., Sulik, K. K., Fish, E. W., Baker, L. K., Dehart, D. B., & Parnell, S. E. (2016). Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. Neurotoxicology and Teratology, 58, 15–22.
Ginsburg, B. C., Schulze, D. R., Hruba, L., & McMahon, L. R. (2012). JWH-018 and JWH-073: Δ9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. The Journal of Pharmacology and Experimental Therapeutics, 340, 37–45.
Giorgetti, A., Busardò, F. P., Tittarelli, R., Auwärter, V., & Giorgetti, R. (2020). Post-mortem toxicology: A systematic review of death cases involving synthetic cannabinoid receptor agonists. Frontiers in Psychiatry, 11, 464.
Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., & Hart, C. L. (2014). A survey of synthetic cannabinoid consumption by current cannabis users. Substance Abuse, 35, 184–189.
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998). Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8268–8273.
Hirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. T., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6), 642–649.
Howlett, A. C., & Abood, M. E. (2017). CB1 and CB2 receptor pharmacology. Advances in Pharmacology, 80, 169–206.
Jacobus, J., & Tapert, S. F. (2014). Effects of cannabis on the adolescent brain. Current Pharmaceutical Design, 20(13), 2186–2193.
Kim, D., & Thayer, S. A. (2001). Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. The Journal of Neuroscience, 21(10), RC146.
Lenzi, M., Cocchi, V., Cavazza, L., Bilel, S., Hrelia, P., & Marti, M. (2020). Genotoxic properties of synthetic cannabinoids on TK6 human cells by flow cytometry. International Journal of Molecular Sciences, 21(3), 1150.
Livne, O., Shmulewitz, D., Lev-Ran, S., & Hasin, D. S. (2019). DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug and Alcohol Dependence, 195, 170–177.
Livny, A., Cohen, K., Tik, N., Tsarfaty, G., Rosca, P., & Weinstein, A. (2018). The effects of synthetic cannabinoids (SCs) on brain structure and function. European Neuropsychopharmacology, 28(9), 1047–1057.
Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525.
Malyshevskaya, O., Aritake, K., Kaushik, M. K., Uchiyama, N., Cherasse, Y., Kikura-Hanajiri, R., & Urade, Y. (2017). Natural (Δ9-THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB1 receptor. Scientific Reports, 7(1), 10516.
Mashhoon, Y., Sava, S., Sneider, J. T., Nickerson, L. D., & Silveri, M. M. (2015). Cortical thinness and volume differences associated with marijuana abuse in emerging adults. Drug and Alcohol Dependence, 155, 275–283.
Mathews, E. M., Jeffries, E., Hsieh, C., Jones, G., & Buckner, J. D. (2019). Synthetic cannabinoid use among college students. Addictive Behaviors, 93, 219–224.
Melis, M., De Felice, M., Lecca, S., Fattore, L., & Pistis, M. (2013). Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats. Frontiers in Integrative Neuroscience, 7, 93.
Mensen, V. T., Vreeker, A., Nordgren, J., Atkinson, A., de la Torre, R., Farré, M., Ramaekers, J. G., & Brunt, T. M. (2019). Psychopathological symptoms associated with synthetic cannabinoid use: A comparison with natural cannabis. Psychopharmacology (Berl), 236(9), 2677–2685.
Mereu, G., Fà, M., Ferraro, L., Cagiano, R., Antonelli, T., Tattoli, M., Ghiglieri, V., Tanganelli, S., Gessa, G. L., & Cuomo, V. (2003). Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4915–4920.
Navarrete, F., García-Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., Femenía, T., & Manzanares, J. (2020). Cannabis use in pregnant and breastfeeding women: Behavioral and neurobiological consequences. Frontiers in Psychiatry, 11, 586447.
Ossato, A., Canazza, I., Trapella, C., Vincenzi, F., De Luca, M. A., Rimondo, C., Varani, K., Borea, P. A., Serpelloni, G., & Marti, M. (2016). Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. Progress in Neuropsychopharmacology and Biological Psychiatry, 67, 31–50.
Ossato, A., Uccelli, L., Bilel, S., Canazza, I., Di Domenico, G., Pasquali, M., Pupillo, G., De Luca, M. A., Boschi, A., Vincenzi, F., Rimondo, C., Beggiato, S., Ferraro, L., Varani, K., Borea, P. A., Serpelloni, G., De-Giorgio, F., & Marti, M. (2017). Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48: Behavioral, neurochemical, and dopamine transporter scan imaging studies in mice. Frontiers in Psychiatry, 8, 130.
Pertwee, R. G. (2001). Cannabinoids and the gastrointestinal tract. Gut, 48(6), 859–867.
Pertwee, R. G. (2008). Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond. Addiction Biology, 13(2), 147–159.
Saez, T. M., Aronne, M. P., Caltana, L., & Brusco, A. H. (2014). Prenatal exposure to the CB1 and CB2 cannabinoid receptor agonist WIN 55,212-2 alters migration of early-born glutamatergic neurons and GABAergic interneurons in the rat cerebral cortex. Journal of Neurochemistry, 129(4), 637–648.
Sagheddu, C., Traccis, F., Serra, V., Congiu, M., Frau, R., Cheer, J. F., & Melis, M. (2021). Mesolimbic dopamine dysregulation as a signature of information processing deficits imposed by prenatal THC exposure. Progress in Neuropsychopharmacology and Biological Psychiatry, 105, 110128.
Schoeder, C. T., Hess, C., Madea, B., Meiler, J., & Müller, C. E. (2018). Pharmacological evaluation of new constituents of “Spice”: Synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology, 36, 385–403.
Schreiber, S., Bader, M., Lenchinski, T., Meningher, I., Rubovitch, V., Katz, Y., Cohen, E., Gabet, Y., Rotenberg, M., Wolf, E. U., & Pick, C. G. (2019). Functional effects of synthetic cannabinoids versus Δ9-THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. Addiction Biology, 24(3), 414–425.
Shabani, M., Hosseinmardi, N., Haghani, M., Shaibani, V., & Janahmadi, M. (2011). Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring. Neuroscience, 172, 139–152.
Shapira, B., Rosca, P., Berkovitz, R., Gorjaltsan, I., & Neumark, Y. (2020). The switch from one substance-of-abuse to another: Illicit drug substitution behaviors in a sample of high-risk drug users. PeerJ, 8, e9461.
Struik, D., Sanna, F., & Fattore, L. (2018). The modulating role of sex and anabolic-androgenic steroid hormones in cannabinoid sensitivity. Frontiers in Behavioral Neuroscience, 12, 249.
Sun, X., & Dey, S. K. (2014). Synthetic cannabinoids and potential reproductive consequences. Life Sciences, 97(1), 72–77.
Szutorisz, H., & Hurd, Y. L. (2018). High times for cannabis: Epigenetic imprint and its legacy on brain and behavior. Neuroscience and Biobehavioral Reviews, 85, 93–101.
Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology (Philadelphia, Pa), 54(1), 1–13.
Tanda, G. (2016). Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg. Psychopharmacology (Ber), 233(10), 1845–1866.
Tomiyama, K., & Funada, M. (2014). Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: The involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicology and Applied Pharmacology, 274(1), 17–23.
Trezza, V., Cuomo, V., & Vanderschuren, L. J. (2008). Cannabis and the developing brain: Insights from behavior. European Journal of Pharmacology, 585(2-3), 441–452.
Umut, G., Evren, C., Atagun, M. I., Yilmaz Cengel, H., Bozkurt, M., & Keskinkilic, C. (2020). Impact of at least 2 years of synthetic cannabinoid use on cognitive and psychomotor functions among treatment-seeking male outpatients. Cannabis and Cannabinoid Research, 5(2), 164–171.
UNODC. (2018). Analysis of drug markets. Opiates, cocaine, cannabis, synthetic drugs. https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_3_DRUG_MARKETS.pdf. Accessed 2 Nov 2020.
UNODC. (2019). Global overview of drug demand and supply. https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_DRUG_DEMAND.pdf. Accessed 2 Nov 2020.
UNODC. (2020). World drug report 2020. Cross-cutting issues: Evolving trends and new challenges. https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_4.pdf. Accessed 2 Nov 2020.
Wang, X., Dow-Edwards, D., Anderson, V., Minkoff, H., & Hurd, Y. L. (2004). In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biological Psychiatry, 56(12), 909–915.
Wiley, J. L., Marusich, J. A., Lefever, T. W., Antonazzo, K. R., Wallgren, M. T., Cortes, R. A., Patel, P. R., Grabenauer, M., Moore, K. N., & Thomas, B. F. (2015). AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and potency of novel synthetic cannabinoids in producing Δ9-tetrahydrocannabinol-like effects in mice. The Journal of Pharmacology and Experimental Therapeutics, 354(3), 328–339.
Wiley, J. L., Lefever, T. W., Glass, M., & Thomas, B. F. (2019). Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. Neurotoxicology, 73, 161–167.
Wilkerson, J. L., Schulze, D. R., & McMahon, L. R. (2019). Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments. PLoS One, 14(3), e0209947.
Wojcieszak, J., Krzemień, W., & Zawilska, J. B. (2016). JWH-133, a selective cannabinoid CB2 receptor agonist, exerts toxic effects on neuroblastoma SH-SY5Y cells. Journal of Molecular Neurosciences, 58(4), 441–445.
Zawilska, J. B., & Wojcieszak, J. (2014). Spice/K2 drugs – more than innocent substitutes for marijuana. International Journal of Neuropsychopharmacology, 7(3), 509–525.
Zorlu, N., Angelique Di Biase, M., Kalaycı, Ç. Ç., Zalesky, A., Bağcı, B., Oğuz, N., Gelal, F., Beşiroğlu, L., Gülseren, Ş., Sarıçiçek, A., Bora, E., & Pantelis, C. (2016). Abnormal white matter integrity in synthetic cannabinoid users. European Neuropsychopharmacology, 26(11), 1818–1825.
Acknowledgments
Supported by the Medical University of Lodz, Poland (Grant No 503/3-011-01/503-31-002-19), and Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017SXEXT5) and Regione Sardegna (RASSR03071), Italy.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Zawilska, J.B., Kuczyńska, K., Bratzu, J., Fattore, L. (2021). Neurotoxicity of Exogenous Cannabinoids. In: Kostrzewa, R.M. (eds) Handbook of Neurotoxicity. Springer, Cham. https://doi.org/10.1007/978-3-030-71519-9_206-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-71519-9_206-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71519-9
Online ISBN: 978-3-030-71519-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences